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‘biomedicine’).	As	 recipients	of	health	care	or	as	participants	 in	biomedical	 research,	children	have	
benefitted	 greatly	 from	 the	 advances	 in	 biomedicine.	 Yet,	 the	 rapid	 developments	 in	 biomedicine	
also	hold	(potentially)	adverse	effects	for	children,	and	have	far	reaching	implications	for	their	rights	
and	 interests.	 International	 and	 European	 legal	 instruments	 and	 standards	 relating	 to	 biomedicine	



















The	 report	provides	 an	extensive	 analysis	of	 the	 relevant	human	 rights	of	 children,	with	particular	
attention	on	the	UN	Convention	on	the	Rights	of	the	Child	(CRC)	in	relation	to	biomedical	challenges	
(chapter	2).	It	then	explores	the	relevant	biomedical	legal	instruments,	including	soft	law	standards,	
offering	 a	 specific	 focus	 on	 the	 Council	 of	 Europe	 Convention	 on	 Human	 Rights	 and	 Biomedicine	
(CHRB,	also	known	as	the	Oviedo	Convention)	and	other	relevant	European	instruments	(chapter	3).	
Focusing	on	the	abovementioned	areas	of	concern,	the	report	subsequently	identifies	the	gaps	and	




with	 children’s	 rights,	 invest	 in	 awareness	 raising,	 education	 and	 trainings	 to	 ensure	 effective	
implementation	of	standards	in	practice,	consider	additional	standard	setting	on	specific	themes,	and	
conduct	 a	mapping	 on	 legislative	 frameworks	 and	 practices	 of	 the	 47	 Council	 of	 Europe	Member	
States	in	relation	to	children	and	biomedical	issues.	
The	report	concludes	with	a	bird’s-eye	view	and	explores	the	over-arching	and	general	observations	





concentrates	 on	 three	 over-arching	 themes.	 The	 first	 theme	 consent,	 autonomy	 and	 legal	
representation	of	children	by	parents	or	others	pays	particular	attention	to	the	special	and	complex	










friendly	 justice	 and	 remedies	 and	 provide	 specific	 guidance	 to	member	 states	 in	 this	 regard.	 The	
report	concludes	by	referring	to	additional	cross-cutting	 issues:	privacy	and	confidentiality,	the	 role	
of	 medical	 professionals	 and	 the	 role	 of	 non-state	 actors,	 such	 as	 pharmaceutical	 companies,	
insurance	 companies	 and	 research	 institutes,	 in	 relation	 to	 children’s	 rights	 in	 biomedicine.	 In	
addition	 to	 the	 specific	 recommendations	 identified	 in	 chapter	 4,	 the	 report	 concludes	 with	 five	
general	 recommendations	 for	 the	Council	of	 Europe	 towards	establishing	a	 roadmap	 for	 children’s	
rights	in	biomedicine	(Chapter	5,	Annex	II).	
This	report	offers	a	comprehensive	and	extensive	analysis	of	children’s	rights	and	biomedicine,	from	
both	an	 international	and	European	perspective.	 It	 identifies	and	explores	the	main	challenges	and	
gaps	 in	 the	 existing	 legal	 framework	 and	 practices,	 and	 provides	 specific	 and	 general	
recommendations	 for	 establishing	 a	 roadmap	 by	 the	 Council	 of	 Europe	 to	 address	 the	 special	
position	of	children	in	biomedicine.	Its	recommendations,	in	particular,	promote	the	view	of	children	
as	rights	holders	and	accommodate	their	rights	and	evolving	capacities	in	relation	to	their	health	and	
care.	 Still,	 safeguarding	 children’s	 rights	 and	 interests	 in	 biomedicine	 cannot	 be	 achieved	 by	 the	







































new	forms	of	 treatment	can	have	on	 the	 rights	of	children.1	 It	 is	generally	 thought	 that	 the	health	
and	well-being	of	children	–	as	well	as	others	–	can	 immensely	benefit	 from	the	advances	made	 in	
the	domain	of	biomedicine,	but	at	 the	same	time	there	 is	considerable	concern	about	 its	potential	
adverse	effects	on	children	and	their	rights.	
The	 aim	 of	 this	 report	 is	 to	 answer	 the	 question	 whether	 the	 existing	 body	 of	 international	 and	
European	 law	 provides	 sufficient	 respect	 for	 and	 appropriate	 protection	 to	 children’s	 rights	 with	
respect	to	biomedicine.	 In	doing	so,	 this	report	builds	on	the	outcomes	of	the	report	The	Rights	of	

























4	 UN	 General	 Assembly,	 Convention	 on	 the	 Rights	 of	 the	 Child,	 20	 November	 1989,	 UN	 Treaty	 Series,	 vol	 1577,	 p.	 3	
(hereinafter:	‘CRC’).	
5	 Council	 of	 Europe,	Convention	 for	 the	Protection	of	Human	Rights	 and	Dignity	of	 the	Human	Being	with	 regard	 to	 the	
Application	of	Biology	and	Medicine:	Convention	on	Human	Rights	and	Biomedicine	(1997)	(hereinafter:	‘CHRB’);	Council	of	
Europe,	 Additional	 Protocol	 on	 the	 Prohibition	 of	 Cloning	 Human	 Beings	 (1998)	 (hereinafter:	 ‘Protocol	 concerning	
Cloning’);	Council	of	Europe,	Additional	Protocol	concerning	Transplantation	of	Organs	and	Tissues	of	Human	Origin	(2002)	
(hereinafter:	 ‘Protocol	 concerning	 Transplantation’);	 Council	 of	 Europe,	 Additional	 Protocol	 concerning	 Biomedical	
Research	 (2005)	 (hereinafter:	 ‘Protocol	 concerning	 Biomedical	 Research’);	 and	 Council	 of	 Europe,	 Additional	 Protocol	
concerning	Genetic	Testing	for	Health	Purposes	(2008)	(hereinafter:	‘Protocol	concerning	Genetic	Testing’).	
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European	 legal	 instruments,	 but	 also	 identifies	 which	 standards	 are	 relevant	 and	 appropriate	 for	




In	 general,	 international	 and	 European	 human	 rights	 standards	 entail	 (negative	 and	 positive)	
obligations	for	States.	States	are	the	primary	duty	bearers	and	have	the	responsibility	to	implement	
international	and	European	 law	relating	to	the	 individual’s	human	rights.	This	may	 imply	regulating	
the	 relations	between	private	persons,	or	protecting	 individuals	 against	encroachments	upon	 their	
rights	 by	 others.	 This	 is	 not	 different	 with	 regard	 to	 the	 human	 rights	 of	 children	 (i.e.	 children’s	
rights).	However,	the	CRC	as	well	as	European	human	rights	standards	have	specific	implications	for	




be	 argued	 that	 parents	 have	 certain	 responsibilities	 towards	 children	on	 the	basis	 of	 international	
and	European	children’s	rights	standards,	for	example	in	relation	to	the	child’s	best	interests	and	the	
right	to	be	heard.7		








(e.g.	 pharmaceutical	 industry,	 insurance	 companies	 and	 research	 institutions).	 This	 is	 of	 particular	
relevance	 in	 light	 of	 the	 growing	 interest	 in	 non-state	 actors’	 (e.g.	 private	 sector,	 businesses,	 etc.)	
responsibilities	 concerning	 human	 rights.8	 Due	 to	 the	 scope	 and	 aim	 of	 this	 report,	 the	 role	 and	











the	 field	 of	 biology	 and	 medicine,	 notably	 biomedical	 research	 and	 health	 care	 (i.e.	 ‘therapy’	 or	
‘care’).	The	primary	purpose	of	research	concerning	children	 is	to	develop	or	contribute	to	medical	
knowledge	 eventually	with	 the	 aim	 to	 improve	 forms	of	 treatment	 for	 all	 children.	 Research,	 thus	
described,	may	have	therapeutic	effects	on	individual	children	but	this	is	not	its	prime	goal.	Therapy,	
or	physical	and	mental	health	care,	 is	aimed	at	 treating	a	particular	child	and	 improving	his	or	her	














The	 term	 ‘child’	 is	 used	 to	 refer	 to	 persons	 from	 birth	 to	 the	 age	 of	 18,10	 even	 though	 we	 will	








Uppsala	 Report.	 The	 conclusions	 of	 this	 chapter	 are	 defined	 in	 terms	of	 recommendations	 for	 the	
Council	of	Europe,	suggesting	measures	the	Council	could	take,	at	the	intergovernmental	level	and	as	



























positive	 European	 human	 rights	 law	 –	 whether	 under	 the	 European	 Social	 Charter	 or	 under	 the	
European	Convention	[of	Human	Rights]’	adding	that	‘health	care	is	prerequisite	for	the	preservation	
of	human	dignity’.12	Therefore,	 the	concept	of	 ‘dignity’,	 considered	 to	be	 inherent	 to	every	human	
being,13	constitutes	an	essential	value	to	be	upheld	both	by	the	CRC	and	the	CHRB.14	In	fact,	concerns	
about	 threats	 to	human	dignity	as	a	 result	of	 ‘misuse	of	biology	and	medicine’	were	an	 important	
motivation	for	the	adoption	of	CHRB.15	
Indeed,	the	precise	meaning	of	human	dignity	is	not	always	clear.	According	to	the	European	Court	of	
Human	Rights	 (ECtHR),	 dignity	 concerns	 ‘a	 particularly	 vague	 concept,	 and	 one	 subject	 to	 random	



















‘constraint’,	 a	 term	 used	 to	 express	 that	 human	 dignity	 sometimes	 necessitates	 the	 taking	 of	
measures	 to	protect	 the	 inviolability	 and	 integrity	 of	 human	beings.18	As	we	will	 see,	 the	 inherent	
tension	 between	 ‘empowerment’	 and	 ‘constraint’	 is	 particularly	 topical	 with	 respect	 to	 children	
where	it	 is	felt	that	children	should	be	prevented	to	make	certain	decisions	autonomously	to	avoid	




and	 beliefs,	 and	 to	 make	 their	 own	 choices.	 Thus,	 autonomy	 is	 a	 principle	 closely	 connected	 to	
human	 dignity	 as	 empowerment.	 In	 2005,	 the	 ECtHR	 declared	 personal	 autonomy	 to	 be	 a	 right,	
particularly	with	 respect	 to	making	 choices	 about	 one’s	 body	 (integrity),20	 notably	with	 respect	 to	




in	doubt	and	 the	person’s	 competency	 is	questioned,	 the	State	 is	entitled	 to	 take	appropriate	and	
proportionate	measures	(e.g.,	taking	a	child	into	care	or	appointment	of	a	guardian25).		
Competence	is	commonly	considered	a	prerequisite	to	exercise	autonomy.	By	law	individuals	should	
have	 the	 mental	 capacity	 to	 exercise	 autonomy,	 notably	 in	 case	 of	 decisions	 that	 can	 have	 far	
reaching	and	irreversible	consequences	for	their	 lives.	This	 is	why	human	rights	 law	often	seems	to	
restrict	 the	 autonomy	 of	 children.	 This	 relates	 to	 the	 concept	 of	 the	 child’s	 evolving	 capacities,	
holding	 that	 the	 extent	 to	 which	 children	 are	 considered	 competent	 depends	 on	 their	 age	 and	
maturity,	and	 that	 it	progresses	with	 time	and	experience.	This	 requires	 to	 recognise	 that	 children	
can	be	competent	 to	make	certain	decisions	 in	 relation	 to	 their	 treatment	and	care,	and	 that	 they	
should	be	allowed,	empowered	and	encouraged	to	exercise	their	rights.	
Integrity	






















Torture,	 inhumane	 and	 degrading	 forms	 of	 treatment	 are	 considered	 flagrant	 violations	 of	 human	
dignity	and	 integrity,	and	are	absolutely	prohibited	under	the	Covenant	on	Civil	and	Political	Rights	
(CCPR)	 and	 the	 European	 Convention	 on	 Human	 Rights	 (ECHR).29	 This	 is	 also	 important	 from	 a	
children’s	 rights	perspective	 since	 children	have	 the	 right	 to	protection	 from	all	 forms	of	 violence,	
including	 the	 most	 heinous	 forms	 amounting	 to	 ‘torture	 or	 other	 forms	 of	 cruel,	 inhuman	 or	
degrading	treatment’.30	The	ECtHR	has	in	this	respect	emphasised	that	dignity	and	integrity	require	
particular	 attention	 where	 a	 child	 is	 the	 victim	 of	 violence.31	 At	 the	 same	 time,	 the	 ECtHR	 has	
repeatedly	held	that	interventions	to	which	a	person	is subjected	against	his	or	her	will,	which	are	of	
therapeutic	necessity	from	the	point	of	view	of	established	principles	of	medicine,	cannot	in	principle	











very	 explicit	 on	 this	 point	 and	 obligates	 States	 to	 ensure	 reasonable	 accommodations	 for	 persons	
with	disabilities	to	secure	the	enjoyment	of	human	rights	on	an	equal	basis.34	The	CRC	also	requires	






28	 CRC	 Committee	 &	 CEDAW	 (2016),	 Joint	 general	 recommendation	 No.	 31	 of	 the	 Committee	 on	 the	 Elimination	 of	
Discrimination	against	Women/General	Comment	No.	18	of	the	Committee	on	the	Rights	of	the	Child	on	harmful	practices.	
29	 Article	 3	 Council	 of	 Europe,	 European	 Convention	 for	 the	 Protection	 of	 Human	 Rights	 and	 Fundamental	 Freedoms,	
November	1950	(hereinafter:	‘ECHR’);	See	also	ECtHR	15	November	1996,	Chahal	v.	the	UK	(GC),	Appl.	No.	22414/93,	para.	
79;	See	also	Article	7	UN	General	Assembly,	International	Convention	on	Civil	and	Political	Rights,	16	December	1966,	UN	






34	Article	 2	UN	General	Assembly,	Convention	on	 the	Rights	 of	 Persons	with	Disabilities,	 24	 January	 2007,	A/RES/61/106	
(hereinafter:	‘CRPD’).	
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of	human	rights,	and	 is	 therefore	considered	a	core	human	right.	The	right	 to	access	 to	 justice	has	





right	 to	 receive	 information	 in	 relation	 to	 transplantation39	 or	 protection	 of	 data	 derived	 from	
genetic	testing).40	As	will	be	further	discussed,	in	light	of	the	complex	and	sensitive	nature	of	conflicts	
in	the	field	of	biomedicine,	the	need	for	speedy	resolutions,	and	the	wish	to	enable	a	child-friendly	






proceedings	 should	 respect	 and	protect	 the	 rights	 of	 children,	 and	 that	 justice	 shall	 be	 accessible,	
age-appropriate,	speedy,	diligent,	and	adapted	to	and	focused	on	the	needs	and	rights	of	children.42	
Specifically,	 the	CFJ	Guidelines	anchor	the	child’s	 right	 to	 information,	assistance,	participation	and	
protection,	with	due	consideration	of	the	child’s	level	of	maturity.	They	apply	to	judicial	proceedings,	
as	well	as	to	proceedings	before	competent	authorities,	such	as	health	care	providers.43	Thus,	the	CFJ	
Guidelines	 are	 relevant	 for	 children	 and/or	 parents	 that	 may	 require	 judicial	 or	 administrative	







36	 Council	 of	 Europe,	 Guidelines	 of	 the	 Committee	 of	 Ministers	 of	 the	 Council	 of	 Europe	 on	 Child-Friendly	 Justice,	 17	
November	 2010,	 para.	 III(D)(1)-(2)	 (hereinafter:	 ‘CFJ	 Guidelines’);	 Article	 1	 Protocol	 concerning	 Biomedical	 Research;	
Council	of	Europe,	Council	of	Europe	Guidelines	on	Child-Friendly	Health	Care,	(2011),	para.	III(A)(9),	III(B)(10)	(hereinafter:	
‘CFHC	Guidelines’);	Council	of	Europe,	Recommendation	CM/Rec(2012)2	of	the	Committee	of	Ministers	to	Member	States	






















protection	 to	 their	 rights	 in	 care.47	 The	 CRC	 Committee,	 in	 particular,	 notes	 that	 children	 with	
disabilities	 are	prone	 to	discrimination	 in	 relation	 to	 their	 right	 to	health,	 participation,	 protection	
and	 physical	 integrity.	 The	 CRC	 Committee	 requires	 that	 children	 with	 disabilities	 enjoy	 ‘full	 and	
decent	life	conditions’,48	and	that	they	should	have	a	right	to	special	care	and	assistance.49	Yet,	the	
CRC	 Committee	 has	 expressed	 concern	 that	 children	 with	 disabilities	 are	 discriminated	 against,	




The	 CRC	 holds	 that	 in	 all	 actions	 concerning	 children,	 the	 best	 interests	 of	 the	 child	 shall	 be	 ‘a	




consider	 the	 best	 interests	 of	 the	 child	 as	 a	 primary	 consideration	 is	 not	 an	 obligation	 to	merely	




















The	 concept	 of	 the	 best	 interests	 of	 the	 child	 is	 also	 recognised	 in	 European	 legal	 systems.54	 The	
CHRB	stipulates	that	the	best	interests	of	the	person	concerned	should	be	a	leading	consideration.55	









background,	 family	 situation,	 and	health	 condition.62	 The	principle	of	best	 interests,	 then,	 requires	
States	 to	 conduct	 a	 child-specific	 evaluation,	 considering	 the	 child’s	 specific	 needs	 and	 particular	
situation.	
General	Principle	3:	Right	to	life,	survival	and	development	
The	 CRC	 holds	 that	 every	 child	 has	 an	 ‘inherent	 right	 to	 life’	 and	 requires	 States	 to	 ensure	 to	 the	
maximum	 extent	 possible	 the	 survival	 and	 development	 of	 children.63	 The	 CRC	 Committee	 has	
interpreted	 ‘development’	 in	 a	broad	and	holistic	 sense,	 covering	also	 the	 child’s	physical,	mental,	
and	psychological	 development	 and	growth.	 This	 third	 general	 principle	of	 the	CRC	 is	 of	 particular	
significance	in	relation	to	health	care64	and	to	biomedicine	as	a	whole.			
The	 right	 to	 life	 obviously	 is	 one	 of	 the	 most	 fundamental	 rights	 of	 the	 child.	 In	 the	 context	 of	
biomedicine,	 the	 scope	 of	 the	 right	 to	 life	 is	 a	 matter	 of	 concern	 and	 the	 question	 is	 whether	 it	
extends	to	unborn	children	and	to	autonomously	chosen	end	of	life	decisions	–	particularly	given	the	
concerns	raised	in	the	Uppsala	Report.	While	there	is	no	universal	consensus	on	these	issues,	the	CRC	
















60	Wade	K.,	Melamed	 I.	 and	Goldhagen	 J.	 (2016),	 ‘Beyond	Bioethics:	A	Child	Rights-Based	Approach	 to	Complex	Medical	
Decision-Making’,	Perspect	Biol	Med	58(3):332-40	(333)	(hereinafter:	‘Wade	et	al.	(2016)’;	CRC	GC	14,	supra	note	52,	p.	2.	
61	CRC	GC	14,	supra	note	52,	p.	5,	9.	
62	Kilkelly,	U.	 (2015),	 ‘Health	and	Children's	Rights’,	 in:	W.	Vandenhole,	 E.	Desmet,	D.	Reynaert	and	S.	 Lembrechts	 (eds),	










either	 exclude	 embryos	 and	 fetuses	 from	 their	 scope,	 or	 provide	 them	 with	 limited	 protection.67	
Thus,	 fetuses	 and	 embryos	 may	 enjoy	 certain	 legal	 protection	 and	 status,	 depending	 on	 the	
particular	context,	and	according	to	the	margin	of	appreciation	of	States.	This	complex	and	sensitive	
issue	 raises	 questions	 on	whether	 the	 right	 to	 life	 is	 applicable,	what	 safeguards	 should	 be	 put	 in	
place,	and	how	the	conflicting	interests	should	be	weighted	and	resolved.		
The	 same	 holds	 true	with	 respect	 to	 end	 of	 life	 decisions	 that	 are	 nowadays	 increasingly	 seen	 as	
expressions	 of	 autonomy.	 In	 relation	 to	 children,	 the	 issue	 of	 end	 of	 life	 decisions	 also	 raises	
questions	as	to	the	role	of	parents,	and	to	what	extent	parents	can	make	 irreversible	decisions	 for	






CRC	 and	 has	 been	 broadly	 interpreted	 as	 a	 right	 to	 participation.	 Under	 the	 Council	 of	 Europe	
Recommendation	 on	 the	 Participation	 of	 Children69,	 participation	 is	 defined	 as	 the	 right,	 means,	
space	 and	 opportunity	 to	 express	 views	 freely,	 be	 heard,	 and	 be	 able	 to	 contribute	 to	 decision-






making	 processes.	 Specifically,	 the	 organisation	 of	 health-care	 services	 needs	 to	 be	 informed	 by	
hearing	children,	and	children	should	be	actively	consulted	 in	 relation	 to	health	care	related	plans,	
policies	and	 legislation.	To	enable	meaningful	participation	 in	relation	to	their	own	health,	children	
and	 their	 parents	 need	 to	 be	 provided	 with	 all	 relevant	 information,	 and	 be	 offered	 support.	
Children,	 in	particular,	 are	entitled	 to	 receive	 child-friendly	and	age	appropriate	 information,	 in	an	














under	 national	 law,	 the	 views	of	 the	 child,	 regardless	 of	 his	 or	 her	 legal	 ability	 to	 consent,	 should	






have	 the	 right	 and	 duty	 to	 provide	 guidance	 and	 direction	 to	 the	 child.	 As	 a	 corollary	 States	 are	
required	to	recognise	parents’	responsibilities,	rights	and	duties.73	This	means	that	parents	have	an	
important	role	and	responsibility	 in	protecting,	respecting	and	fulfilling	children’s	 rights,	also	 in	the	
field	of	health	and	biomedicine.	But	how	 to	 interpret	 these	 rights	 and	duties,	often	 referred	 to	as	
‘parental	authority’?	
As	 the	 CRC	 views	 children	 as	 right	 holders,	 it	 requires	 that	 parents	 are	 guided	 in	 their	 decision	
making	by	the	best	interest	of	the	child,74	and	that	they	take	into	account	the	interests	and	rights	of	
children,	 as	 well	 as	 their	 evolving	 capacities	 and	 competences	 (see	 under	 evolving	 capacities).75	
Under	the	CHRB,	parents	can	authorize	and	withhold	consent	to	medical	intervention,	treatment	and	
participation	in	research	on	behalf	of	their	children,76	and	the	ECtHR	has	identified	the	involvement	
of	parents	 in	medical	decision-making	under	 the	protection	of	private	and	 family	 life,	according	 to	
Article	8	ECHR.77	Yet,	parental	decision-making	can	be	limited	when	it	can	infringe	fundamental	rights	






often	 determined	 by	 their	 parents	 (or	 other	 legal	 representatives	 as	 prescribed	 by	 law).	 This	 is	
notably	 because	 children	 are	 not	 always	 considered	 to	 be	 competent	 to	 consent	 or	 refuse	 to	





















making	 is	 also	meant	 to	 reflect	 the	 interests	 of	 children,	 and	 assist	 them	 in	 exercising	 their	 own	
evolving	autonomy,	and	safeguard	their	rights	and	interests.		
2.4	Specific	rights	of	children	relevant	to	biomedicine	
Three	 human	 rights,	 not	 listed	 above,	 are	 of	 particular	 relevance	 for	 children	 in	 the	 area	 of	
biomedicine	and	will	be	briefly	addressed	below.	
Right	to	identity	
Under	 the	CRC	States	are	 required	 to	 respect	 the	 right	of	 the	child	 to	preserve	his	or	her	 identity,	
including	 nationality,	 name	 and	 family	 relations	 as	 recognised	 by	 law	 without	 unlawful	
interference.80	Personal	 identity	 is	closely	connected	with	human	dignity.	The	ECtHR	acknowledged	
with	 respect	 to	 end	 of	 life	 decisions	 that	 forcing	 individuals	 to	 linger	 on	 in	 old	 age	 or	 in	 states	 of	
advanced	 physical	 or	mental	 decrepitude	may	 conflict	 with	 their	 ideas	 of	 personal	 identity.81	 The	
meaning	 of	 the	 right	 to	 identity,	 however,	 is	 of	 relevance	 for	 more	 of	 the	 biomedical	 concerns	
identified	by	 the	Uppsala	Report.	Personal	 identity	 is,	 for	example,	 also	at	 stake	when	 it	 comes	 to	
receiving	information	about	one’s	descent,	one’s	biological	parents	or	the	truth	about	paternity82	as	
well	as	respect	for	one’s	gender	identity,	according	to	the	ECtHR	‘one	of	the	most	intimate	areas	of	a	





of	 the	 person,	 including	 his	 or	 her	 sexual	 life.86	 In	 relation	 to	 biomedical	 interventions,	 children’s	
right	 to	 privacy	 should	 also	 be	 taken	 into	 account,	 which	 among	 others	 implies	 that	 not	 all	
information	is	automatically	shared	with	parents.	The	ECtHR	also	noted	with	respect	to	the	right	to	
private	life	that	‘respecting	the	confidentiality	of	health	data	is	a	vital	principle	in	the	legal	systems	of	
all	 the	 Contracting	 Parties	 to	 the	 Convention’.87	 Both	 the	 right	 to	 privacy	 as	 well	 as	 the	 issue	 of	










79885/12,	 52471/13	 and	 52596/13;	 Also	 in	 relation	 to	 international	 surrogacy,	 the	 ECtHR	 confirmed	 that	 the	 right	 to	






individuals,	 has	 implications	 for,	 among	 others,	 data	 collection,	 access	 to	 medical	 files	 and	











specifically	 acknowledge	 the	 principles	 of	 participation,	 non-discrimination,	 dignity	 and	 the	 best	
interests	of	 the	 child	 in	 the	 context	of	health-care,	 and	emphasise	 that	 children	 should	be	 treated	
with	care,	sensitivity,	 fairness	and	respect	 in	any	health-related	 intervention,	with	special	attention	
to	their	personal	situation	and	needs.93	
The	right	of	the	child	to	health	 is	of	 imminent	 importance	to	biomedical	research	and	care,	and	all	
the	 areas	 of	 concern	 identified	 by	 the	 Uppsala	 Report.	 Its	 realisation	 requires,	 in	 the	 field	 of	



























This	 chapter	 contains	 a	 description	 of	 international	 and	 European	 legal	 standards	 relevant	 to	 the	
areas	 of	 concern	 and	 challenges	 identified	 in	 the	 Uppsala	 Report.	 We	 will	 particularly	 examine	
whether	 the	 existing	 biomedical	 standards	 have	 child	 specific	 provisions	 and,	 if	 so,	 what	 their	
meaning	is.	
3.1 International	standards	









More	 recent	 human	 rights	 documents,	 like	 the	 CRPD,	 emphasise	 both	 the	 importance	 of	
international	cooperation	in	research	and	access	to	scientific	and	technical	knowledge,	while	at	the	
same	 time	 acknowledging	 the	 right	 of	 children	 to	 autonomy	 and	 express	 their	 views	 ‘on	matters	
affecting	them’	as	well	as	the	principle	of	the	child’s	best	interests.96	To	the	extent	that	international	
documents	on	research	do	contain	child	specific	provisions,	like	the	CRPD,	these	provisions	generally	
only	 seek	 to	 provide	 more	 protection	 to	 children	 – thus	 restricting	 the	 possibilities	 to	 serve	 as	
research	participants	–	by	enhancing	the	criteria	that	would	allow	their	participation.	As	an	example,	
reference	should	be	made	 to	 the	Declaration	of	Helsinki	of	 the	World	Medical	Association	 (WMA).	
This	declaration,	adopted	in	1964,	contains	a	set	of	ethical	principles	that	should	be	adhered	to	when	
performing	biomedical	research	with	human	beings.	According	to	this	declaration	‘Medical	research	
involving	human	subjects	may	only	be	conducted	 if	 the	 importance	of	 the	objective	outweighs	 the	
risks	and	burdens	to	the	research	subjects’.	When	it	comes,	however,	to	involving	‘vulnerable	groups	
and	individuals’	such	as	children	these	should	‘receive	specifically	considered	protection’.97	
Reference	 should	 also	 be	 made	 to	 the	 International	 Ethical	 Guidelines	 for	 Biomedical	 Research	
Involving	 Human	 Subjects,	 adopted	 by	 the	 Council	 for	 International	 Organizations	 of	 Medical	
Sciences	 (CIOMS).	 These	 standards	 emphasise	 the	 ethical	 justification	 and	 scientific	 validity	 of	
biomedical	research	involving	human	subjects.	Besides	acknowledging	the	right	to	informed	consent,	
the	 standards	 contain	 a	 guideline	with	 respect	 to	 involving	 children	as	 research	participants,	 in	 an	
effort	to	optimally	guarantee	their	rights	and	interests.98	
																																								 																				










A	 similar	 tension	between	potential	benefits	 and	 threats	 is	 imminent	with	 respect	 to	 international	
standards	on	physical	and	mental	health	care.	Provisions	on	the	right	to	health	and	health	care,	like	
Article	12	of	the	Covenant	on	Economic,	Social	and	Cultural	Rights	(CESCR),99	stress	the	importance	of	
equal	 access	 to	 and	 the	 availability	 of	 health	 care,	 whereas	 other	 documents	 tend	 to	 protect	
individuals	 from	 unwanted	 health	 care	 interventions	 by	 emphasising	 consent	 and	 free	 choice.	 For	
example,	 Article	 17	 of	 the	 CCPR	 obligates	 States	 to	 offer	 legal	 protection	 against	 the	 ‘arbitrary	 or	
unlawful	 interference’	 of	 a	 person’s	 privacy.100	 Similar	 concerns	 about	 potential	 abuse	 are	
particularly	 echoed	 by	 instruments	 seeking	 to	 prevent	 abuse	 of	 psychiatry.101	 The	 CRC	 Committee	
also	 emphasises	 the	 range	 of	 measures	 States	 should	 take	 in	 order	 to	 attain	 the	 highest	 level	 of	
health.102	While	the	CRC	is	fully	aware	of	the	importance	of	such	principles	as	non-discrimination,	the	
child’s	 best	 interests	 and	 the	 right	 to	 be	 heard,	 the	 CRC	 is	 above	 all	 focused	 on	 achieving	 the	
preconditions	in	which	children	can	live	healthy.	The	CRC	Committee	recommends	States	to	review	
and	consider	allowing	children	to	consent	to	certain	forms	of	medical	treatments	and	interventions,	
giving	 the	 examples	 of	 HIV	 testing	 and	 sexual	 and	 reproductive	 health	 services.	 The	 CRC	 remains	
silent	on	particular	issues	that	relate	to	consent,	refusal	and	the	limitation	that	should	be	placed	on	






prenatal	 health	 care,	 whether	 this	 extents	 to	 preconceptional	 interventions	 and	 how	 to	 assess	
whether	these	techniques	are	consistent	with	human	dignity	and	the	rights	of	the	 (future)	child.	 In	


















105	 See	 for	 example	Article	 24	 para	 2	 (d)	 CRC	 imposing	 a	 duty	 on	 States	 to	 ensure	 appropriate	 pre-natal	 and	 post-natal	
health	care	for	mothers.	
106	UN	(2015),	Global	Strategy	for	Women’s,	Children’s	and	Adolescents’	Health	(2016-2030)	








diagnosis	 affecting	 an	 individual’s	 genome	 shall	 be	 undertaken	 only	 after	 rigorous	 and	 prior	
assessment	of	the	potential	risks	and	benefits	pertaining	thereto	and	 in	accordance	with	any	other	
requirement	 of	 national	 law	 and	 (b)	 on	 the	 basis	 of	 the	 prior,	 free	 and	 informed	 consent	 of	 the	
person	 concerned.110	 This	 declaration	 thus	 clearly	 emphasises	 the	 rights	 to	 autonomy	 and	 to	
protection	of	 (potential)	 research	 subjects.	 Similar	 values	underlie	UNESCO’s	Universal	Declaration	
on	 Bioethics	 and	 Human	 Rights	 (UDBHR,	 2005),	 a	 declaration	 that	 in	 general	 emphasises	 the	
importance	 of	 finding	 a	 proper	 balance	 between	 benefits	 and	 risks	 (‘In	 applying	 and	 advancing	









When	 it	comes	to	gender	modification	techniques	 international	standards	are	still	 relatively	silent.	
The	CRC	Committee	recently	urged	States	not	to	subject	intersex	individuals	to	unnecessary	medical	
or	 surgical	 treatment	 during	 infancy	 or	 childhood,	 and	 to	 provide	 families	 with	 intersex	 children	
adequate	counselling	and	support.	The	UN	Special	Rapporteur	on	Torture	also	recommended	States	
to	 amend	 laws	 that	 fail	 to	 protect	 children	 from	 medically	 unnecessary	 gender-normalizing	
procedures.115	 In	 addition,	 while	 the	 CRC	 Committee	 has	 emphasised	 the	 right	 of	 children,	
particularly	adolescents,	to	respect	for	their	physical	and	psychological	integrity,	gender	identity	and	
emerging	 autonomy,116	 yet	 there	 are	 no	 sufficient	 international	 legal	 standards	 or	 guidance	 in	
relation	to	transgender	children’s	access	to	gender	modification	techniques.		
International	 standards	 on	 transplantation	 care	 express	 concern	 about	 the	 shortage	 of	 available	
organs,	threatening	the	health	and	life	of	persons	in	need	of	a	transplant	organ.	They	equally	stress	
the	 importance	of	 ethical	 and	 legal	 procedures	 to	 increase	 supply	with	 full	 respect	 for	 the	human	
																																								 																				















dignity	 and	 autonomy	 of	 the	 potential	 donor.117	 The	WHO	Guidelines	 ‘exclude	 vulnerable	 persons	
who	are	 incapable	of	fulfilling	the	requirements	for	voluntary	and	knowledgeable	consent’,	such	as	




of	 medical	 practice,	 and	 strongly	 encourages	 all	 National	 Medical	 Associations	 and	 physicians	 to	
refrain	 from	 participating	 in	 euthanasia,	 even	 if	 national	 law	 allows	 it	 or	 decriminalizes	 it	 under	
certain	 conditions.119	 The	UN	Human	Rights	 Committee,	 as	well	 as	 the	 CRC	Committee,	 expressed	
concern	about	the	compatibility	of	the	Dutch	Law	on	the	Termination	of	Life	on	Request	and	Assisted	
Suicide	 (Euthanasia	 Act).120	 Belgian	 law,	 that	 explicitly	 permits	 child	 euthanasia	 under	 strict	
conditions,	also	received	worldwide	critique.121	
3.2 European	standards	
Concern	 about	 unethical	 forms	 of	 biomedical	 research	 that	 would	 be	 in	 contradiction	 with	





can	 become	 a	 research	 participant.126	 Thus,	 according	 to	 these	 standards,	 involving	 children	 in	
biomedical	research	programmes	is	only	permitted	under	exceptional	circumstances.	Yet,	and	as	will	
be	 further	 discussed	 in	 chapter	 4,	 the	 CHRB	 and	 its	 additional	 protocols	 regard	 children	 who	 are	
unable	 to	 consent.	 Children	 under	 this	 category	 are	 then	 provided	with	 additional	 protection	 and	
safeguards,	to	ensure	their	rights	and	interests.	However,	the	age	of	consent	to	medical	treatment	or	




117	WHO	Guiding	 Principles	 on	Human	Cell,	 Tissue	 and	Organ	 Transplantation	 (2010),	 endorsed	 by	 the	 sixty-third	World	
Health	Assembly.	
118	Declaration	of	Istanbul	(2008),	adopted	by	the	participants	in	the	International	Summit	on	Transplant	Tourism	and	Organ	
Trafficking	convened	by	The	Transplantation	Society	and	 International	Society	of	Nephrology	 in	 Istanbul	 (April	30–May	2,	
2008).	
119	WMA	resolution	of	euthanasia	(2002,	and	reaffirmed	in	2013).	




of	 the	 Rights	 of	 the	 Child,	 http://www.prnewswire.com/news-releases/belgian-law-for-child-euthanasia-is-in-violation-of-
the-united-nations-convention-of-the-rights-of-the-child-245344051.html	(last	accessed:	19.6.2017).		










national	 age	 of	 consent,	 children	 can	 still	 require	 special	 assistance	 and	 support	 in	 the	 context	 of	
biomedicine.	 This	may	 refer	 to	 issues	 such	 as	 child-friendly	 information	 and	 communications	with	
medical	 professionals,	 access	 to	 justice	 and	 remedy,	 or	 parental	 support	 and	 assistance.	 The	
European	 Social	 Charter	 (ESC)	 is	 also	 of	 particular	 relevance	 with	 respect	 to	 the	 legal	 framework	
seeking	 to	 regulate	 the	 developments	 in	 the	 field	 of	 biomedicine.	 The	 Revised	 Charter	 reads	 as	
follows:	‘Children	and	young	persons	have	the	right	to	a	special	protection	against	the	physical	and	
moral	hazards	to	which	they	are	exposed.’127	And	the	ESC	further	stipulates	in	general	that	‘Children	
and	 young	 persons	 have	 the	 right	 to	 appropriate	 social,	 legal	 and	 economic	 protection’.128	 These	
obligations	to	protect	are	also	of	great	importance	when	it	comes	to	health	and	biomedical	issues.	
When	 it	comes	to	physical	and	mental	health	care,	European	standards129	seek	to	guarantee	basic	
safeguards	 with	 respect	 to	 informed	 consent,130	 confidentiality,131	 equal	 access,132	 safety133	 and	
quality.134	 Also	 in	 Europe,	 there	 is	 special	 concern	 about	 the	 treatment	 of	 persons	with	 a	mental	
disorder.135	 When	 it	 comes	 to	 persons	 not	 able	 to	 consent,	 the	 CHRB	 stipulates	 that	 the	 best	
interests	of	the	person	concerned	should	be	leading.136		
The	 ECtHR	 has	 interpreted	 the	 right	 to	 life	 as	 requiring	 States	 to	 make	 regulations	 compelling	





guarantee	 children	 receive	 the	 care	 and	 assistance	 they	 need	 and	 to	 protect	 them	 from	 any	
negligence,	violence	or	exploitation,	that	pose	a	serious	threat	to	the	enjoyment	of	their	basic	rights,	
such	as	the	rights	to	life,	to	psychological	and	physical	integrity	and	to	respect	for	human	dignity.138	
States	 are	 required	 to	 guarantee	 the	 right	 of	 children	 to	 care	 and	 assistance,	 including	 medical	


























the	 European	Union	 (EU	Charter)	 states	 that	 ‘Children	 shall	 have	 the	 right	 to	 such	 protection	 and	
care	as	 is	necessary	 for	 their	well-being…’.	The	second	paragraph	of	 this	provision	adds	 that	 ‘In	all	
actions	relating	to	children	(…)	the	child's	best	interests	must	be	a	primary	consideration.’142	
On	a	European	 level,	 there	 is	 ample	discussion	on	 the	 regulation	of	preconceptional	and	prenatal	
interventions143	but	this	 is	 largely	 left	to	 individual	States	 in	the	absence	of	a	European	consensus.	
This	 also	 explains	 why	 this	 issue	 is	 not	 addressed	 by	 the	 CHRB,	 with	 the	 exception	 of	 human	
cloning.144	
On	 a	 European	 level	 a	 number	 of	 standards	 emerged	 in	 response	 to	 concerns	 about	 the	
‘uncontrolled’	developments	and	application	of	genetic	techniques.145	 In	Europe	there	seems	to	be	
particular	 concern	 about	 the	 retrieval	 and	 use	 of	 sensitive	 information	 by	 genetic	 testing	
techniques.146	 This	 also	 holds	 true	 with	 respect	 to	 children147	 and	 other	 vulnerable	 groups.	 With	
respect	 to	 this	 category	 of	 persons,	 the	Additional	 Protocol	 concerning	Genetic	 Testing	 for	Health	
Purposes	 proscribes	 that	 ‘a	 genetic	 test	 on	 this	 person	 shall	 be	 deferred	 until	 attainment	 of	 such	
capacity	unless	that	delay	would	be	detrimental	to	his	or	her	health	or	well-being’	(Article	10).	
European	 standards	 increasingly	 allow	gender	modification	 techniques	 provided	 that	 the	 rights	of	
the	 persons	 concerned	 are	 fully	 respected.148	 PACE	 is	 also	 very	 concerned	 about	 discrimination	
against	 transgender	 persons	 in	 Europe.149	 Both	 the	 ECtHR	 and	 PACE	 call	 on	 States	 to	 abolish	
sterilisation	 and	 other	 compulsory	 medical	 treatment,	 as	 well	 as	 a	 mental	 health	 diagnosis,	 as	 a	
necessary	 legal	 requirement	 to	 recognise	 a	 person’s	 gender	 identity.	 Yet,	 such	 standards	 do	 not	
specifically	relate	to	children.	
Both	 the	 CHRB	 and	 its	 Additional	 Protocol	 concerning	 Transplantation	 of	 Organs	 and	 Tissues	 of	
Human	 Origin	 (Protocol	 concerning	 Transplantation)	 contain	 standards	 with	 respect	 to	
transplantation	care.	The	CHRB	has	two	provisions	on	organ	donations,	with	additional	criteria	to	be	
met	 to	allow	 for	organ	donation	 from	a	child	or	other	vulnerable	person.150	These	provisions	have	







143	 See	 e.g.	 European	 Commission,	 Health	 &	 Consumer	 Protection	 Directorate-General	 (2006),	 Report	 on	 regulation	 of	
















On	a	European	 level	 there	 is	an	ongoing	discussion	on	end	of	 life	decisions.153	 	 In	2002	 the	ECtHR	
found	that	a	‘right	to	die’	cannot	be	derived	from	Article	2	ECHR.154	At	the	same	time	the	ECtHR	held	
that	 patients	 have	 a	 right	 to	 refuse	 treatment,	 including	 life-saving	 treatment.155	 States	 that	 deny	





Many	 international	 and	 European	 organisations	 have	 set	 standards	 in	 the	 areas	 of	 biomedical	
research	 and	 care,	 as	well	– but	 to	 a	 lesser	 extent	– the	 other	 areas	 of	 concern	 identified	 in	 the	
Uppsala	 Report	 (see	 chapter	 1).	 Above	 all,	 these	 standards	 seek	 to	 protect	 individuals	 from	being	





are	 even	 stricter.	 In	 fact,	 children	 are	 in	 various	 instances	 not	 allowed	 to	 participate	 in	 research	
programmes,	to	donate	organs	or	otherwise	to	engage	in	behaviour	that	may	be	seen	as	expressing	
solidarity	unless	very	strict	criteria	are	met.	When	it	comes	to	health	care,	there	are	also	additional	























The	 CHRB	 and	 its	 Additional	 Protocol	 concerning	 Biomedical	 Research	 (Protocol	 concerning	
Biomedical	 Research)	 strictly	 regulate	 biomedical	 research	 involving	 children	 who	 are	 unable	 to	
consent.	 While	 providing	 children	 with	 proven	 technologies,	 treatments	 and	 drugs	 require	 child-
specific	research,	children	should	be	prevented	from	being	involved	in	studies	that	are	disrespectful	
to	human	rights,	notably	children’s	rights.	This	requires	that	the	study	concerned	has	the	potential	to	
benefit	 the	 participant,	 that	 research	 of	 comparable	 effectiveness	 cannot	 be	 carried	 out	 on	
individuals	 capable	 of	 giving	 consent,	 that	 the	 participant	 is	 informed	 and	 does	 not	 object	 (the	
opinion	of	 the	 child	 shall	 be	 considered	as	 an	 increasingly	determining	 factor),	 and	 that	necessary	
authorization	 has	 been	 given.	 Research	 that	 does	 not	 have	 the	 potential	 to	 directly	 benefit	 the	





and	 it	 enables	 a	 case-by-case	 evaluation	 for	 each	 research	 programme,	 which,	 among	 others,	
includes	 the	 intrusiveness	of	 the	 research	 and	 the	 child’s	 views.	However,	 it	 should	be	noted	 that	
such	research	is	not	necessarily	on	strained	terms	with	the	best	interests	of	the	child	principle.		
Furthermore,	 the	 instruments	 set	 safeguards	 for	 research	 concerning	 pregnant	 or	 breastfeeding	
women,158	and	require	that	the	research	includes	guarantees	for	children’s	privacy.159	Thus,	the	CHRB	
and	 the	 Protocol	 concerning	 Biomedical	 Research	 seek	 to	 strike	 a	 balance	 between	 protecting	




(2005),	 para	 89	 (hereinafter:	 ‘Explanatory	 Report	 Protocol	 concerning	 Biomedical	 Research’).	 In	 addition,	 similar	
conditions	 are	 set	 in	 relation	 to	 research	 on	 children's	 biological	 materials	 of	 human	 origin,	 see	 Article	 12-21	 para.	 5	
Rec(2016)6	 on	 research	 on	 biological	 materials	 of	 human	 origin,	 supra	 note	 125;	 Council	 of	 Europe,	 Recommendation	
CM/Rec(2016)6	 of	 the	 Committee	 of	Ministers	 to	Members	 States	 on	 research	 on	 biological	materials	 of	 human	 origin;	
Council	 of	 Europe,	 Explanatory	Memorandum	 -	 Recommendation	 CM/Rec(2016)6	 on	 research	 on	 biological	materials	 of	





particular	 child	 and/or	 children	 as	 a	 group	 on	 the	 other.	 Yet,	 some	 challenges	 and	 gaps	 can	 be	
identified.		
	
1. Children	 able	 to	 consent:	 the	 safeguards	 concerning	 children	 under	 the	 Protocol	 concerning	
Biomedical	 Research	 can	 be	 found	 under	 the	 protection	 of	 ‘persons	 not	 able	 to	 consent’.	 As	
mentioned	in	chapter	3,	basing	the	special	safeguards	on	consent	does	not	sufficiently	address	
the	fact	that	children	below	the	age	of	18	can	be	able,	under	national	law	and/or	in	practice,	to	
consent	 to	 medical	 research	 and	 enjoy	 certain	 decision-making	 powers	 in	 that	 regard.	 Yet,	
despite	 being	 able	 to	 consent,	 children	 still	 require	 special	 assistance	 and	 safeguards	 in	
exercising	 their	 rights.	 It	 is	unclear,	however,	what,	 if	any,	 special	measures	of	protection	and	
assistance	are	available	for	such	children	in	the	context	of	biomedical	research.	Therefore,	it	is	





opinion	 of	 the	 child	 should	 be	 taken	 into	 account	 as	 an	 increasingly	 determining	 factor,	 in	
accordance	with	his	or	her	age	and	maturity.160	The	provision	reflects	the	protective	element	of	
parental	authority,	while	also	requiring	that	in	decision-making	related	to	research,	the	opinion	
and	wishes	of	 the	child	are	 taken	 into	account.	Participation	should	be	understood	broadly	as	
the	obligation	of	decision-makers	(e.g.,	parents,	medical	professionals)	to	hear	and	consider	the	
views	of	the	child	throughout	the	research	process,	 irrespective	of	the	child’s	 legal	capacity	to	
independently	 consent	or	object.	 In	 addition,	 the	 child’s	 right	 to	 participate	 requires	 research	
bodies	and/or	medical	professionals	to	ensure	that	that	research	procedures	are	designed	in	a	
child-sensitive	manner,	 and	 that	mechanisms	 are	 at	 place	 to	 allow	and	encourage	 children	 to	
effectively	participate	in	decision-making	processes.	Yet,	it	is	not	clear	from	these	standards	how	
to	 ensure	 that	 children	 are	 effectively	 heard	 in	 relation	 to	 entering,	 refusing	 or	 withdrawing	
from	research,	as	well	as	throughout	the	course	of	the	research	itself.	Two	additional	elements	
closely	 connected	 with	 the	 broad	 concept	 of	 participation	 in	 that	 regard	 are	 ‘consent’	 and	
‘objection’	 to	 biomedical	 research.	 The	 Protocol	 concerning	 Biomedical	 Research	 holds	 that	 a	
precondition	to	allow	research	on	persons	not	able	to	consent	 is	that	they	do	not	object.161	 In	
relation	to	children,	there	is	a	need	for	a	clear	distinction	between	the	legal	ability	of	the	child	to	
consent	 and	 the	 ability	 to	 object	 to	medical	 research.162	 It	 is	 not	 clear	 how	 the	 CHRB	 or	 the	
Protocol	concerning	biomedical	research	distinguish	between	the	right	to	participation	(which	is	
applicable	to	all	children),	and	the	elements	of	consent	and	objections	to	biomedical	research.	It	
is	 also	 not	 clear	 how	 to	 establish	 a	 child’s	 objection,	 and	what	weight	 should	 it	 be	 accorded	
when	parents	 provide	 authorization	 and	 consent	 on	behalf	 of	 the	 child.	This	 requires	 further	
guidance,	as	well	as	practical	measures	to	enable	children	to	exercise	their	right	to	be	heard	









that	 children	 invited	 to	 participate	 in	 a	 research	 project,	 as	well	 as	 their	 parents,	 receive	 full	
information	 about	 the	 project	 and	 their	 rights.163	 Such	 information	 shall	 be	 delivered	 ‘in	 a	
comprehensible	form’.	Yet,	 it	 is	not	sufficiently	clear	whether	there	 is	an	obligation	to	provide	
children	with	child-friendly	information,	in	an	understandable	language.	This	requires	to	bridge	







principle	of	 the	best	 interests	of	 the	 child	 as	a	 criterion	 in	decision-making.	Thus,	 guidance	 is	




Another	 practical	 challenge	 in	 relation	 to	 parental	 authorization	 concerns	 the	 position	 of	
children	 who,	 during	 or	 following	 the	 research	 project,	 reach	 the	 age	 of	 consent,	 refuse	 or	
withdraw	from	a	research	project.	It	is	unclear	whether	the	existing	legal	standards	require	to	
establish	 a	 ‘re-consent’	 mechanism,	 and	 more	 guidance	 is	 required	 in	 this	 context.	 In	 that	
regard,	it	is	unclear	whether	a	child,	upon	achieving	legal	capacity,	has	a	right	to	decide	on	the	
continued	 storage	 or	 use	 of	 information	 or	 samples	 that	 were	 collected	 from	 him	 or	 her	 for	
biomedical	 research	 purposes,	 with	 the	 authorization	 of	 parents.	 This	 requires	 additional	










required	 to	 establish	 available,	 accessible,	 and	 child-friendly	 redress	 and	 complaints	
mechanisms	 (see	CFJ	Guidelines),	 and	ensure	 children	and	 their	parents	are	 informed	of	 their	
rights,	 the	 instruments	 available	 to	 seek	 remedy	 and	 mechanisms	 to	 review	 decisions.	 It	 is	











6. Research	 on	 embryos	 and	 fetuses:	 the	 protection	 found	 in	 the	 CHRB	 and	 the	 Protocol	
concerning	Biomedical	Research	in	relation	to	embryos	and	fetuses	is	limited.	Although	the	issue	
is	 increasingly	 debated,	 the	 CHRB	 prohibits	 the	 creation	 of	 human	 embryos	 for	 research	
purposes,	 and	 requires	 ‘adequate	protection’	 of	 embryos	 in	 vitro	 in	 research.168	 The	Protocol,	
however,	 does	 not	 apply	 to	 embryos	 in	 vitro	 and	 holds	 that	 particular	 consideration	 shall	 be	
given	 to	 possible	 adverse	 impacts	 on	 the	 health	 of	 an	 embryo	 or	 fetus	 in	 research.169	 It	 is	
recommended	 to	 address	 this	 apparent	 gap	 which	 can,	 in	 the	 absence	 of	 guidance	 and	
standards,	have	far	reaching	 implications	for	 (future)	children	and	their	 rights,	as	well	as	 for	
research	purposes.		
4.2.2	Physical	and	mental	health	care	
The	 right	 to	 equitable	 access	 to	 health	 care	 services	 is	 an	 important	 standard	 in	 relation	 to	
biomedicine.170	 It	 is	 recognised	 that	 proven	 technologies,	 including	 drugs,	 equipment	 and	
intervention,	 should	 be	 introduced	 to	 children,	 and	 that	 States	 have	 a	 positive	 obligation	 to	 take	
measures	 against	 health	 risks	 that	 relate	 to	 children.171	 In	 particular,	 legal	 instruments	 relating	 to	
biomedicine	 anchor	 the	 principle	 of	 non-discrimination	 with	 respect	 to	 the	 application	 of	
biomedicine,172	 conducting	 genetic	 testing,173	 transplantation,174	 and	 biomedical	 research.175	 In	






consent,	 his	 or	 her	 opinion	 shall	 be	 taken	 into	 account	 ‘as	 an	 increasingly	 determining	 factor’,	 in	
















concerning	 the	Protection	of	 the	Human	Rights	 and	Dignity	of	 Persons	with	Mental	Disorder,	supra	note	135;	Article	 12	
para.	 4	 Rec(2016)6	 on	 research	 on	 biological	 materials	 of	 human	 origin,	 supra	 note	 125;	 Rec(2016)6	 on	 research	 on	











can	 be	 able,	 under	 national	 law	 or	 in	 practice,	 to	 consent	 to	 treatment	 and	 enjoy	 certain	
decision-making	powers	in	that	regard.	Yet,	despite	being	able	to	consent,	children	still	require	
special	assistance	and	safeguards	 in	exercising	their	rights,	 for	example	 in	relation	to	receiving	
















friendly	 health	 care	 system,	 which	 includes	 mechanisms	 to	 allow	 and	 encourage	 children	 to	
effectively	participate	 in	decision-making	processes.	 Yet,	 in	practice,	 it	 is	 not	 clear	 from	 these	
standards	how	to	ensure	 that	children	are	effectively	heard	 in	 relation	 to	entering	or	 refusing	
health	care.	Two	additional	elements	closely	connected	with	the	broad	concept	of	participation	
in	 that	 regard	 are	 ‘consent’	 and	 ‘objection’	 to	 health	 care.	 The	 instruments	 relating	 to	
biomedicine	 do	 not	 offer	 guidance	 relating	 to	 children’s	 ability	 to	 give	 or	 refuse	 consent	 to	
proposed	medical	 treatment,	nor	offer	 any	guidance	 in	 relation	 to	 setting	age	 limits	 for	 all	 or	
certain	 biomedical	 procedures.	 The	 same	 holds	 true	 for	 children’s	 objections	 to	 forms	 of	
treatment.	As	previously	discussed,	the	distinction	between	consent,	objection	and	participation	
in	decision-making	requires	further	clarification.	In	particular,	it	is	unclear	what	weight	a	child’s	
objection	 should	 receive,	what	measures	 can	 be	 taken	 by	medical	 professionals	 in	 such	 case,	
and	how	an	objection	relates	to	age	of	consent.	In	Europe,	there	are	variations	in	relation	to	the	

























information’,	 but	 it	 does	 not	 specify	 whether	 such	 information	 is	 to	 be	 provided	 in	 a	 child-








opinion	of	the	child	shall	be	taken	 into	consideration	as	an	 ‘increasingly	determining	factor’	 in	
proportion	 to	his	or	her	age	and	degree	of	maturity,188	but	 it	 remains	unclear	how	to	balance	
between	the	child’s	evolving	capacities	and	views	and	the	parental	authority	in	decision	making	
relating	to	care.	This	requires	additional	guidance	for	States	on	how	to	balance	between	the	





6. Access	 to	 justice	and	remedy:	 the	CHRB	provides	children	with	rights	 in	 the	context	of	health	
care	 and	 biomedicine	 (e.g.	 non-discrimination).	 Yet,	 as	 previously	 discussed,	 the	 instrument	

















we	are	at	 the	doorstep	of	clinical	applications	to	be	 introduced	with	respect	 to	such	techniques	as	
genome	editing	with	embryos.	The	Protocol	concerning	Transplantation	and	the	Protocol	concerning	
Genetic	Testing	do	not	apply	to	embryos	or	fetuses.190	This	may	 lead	to	uncertainty	on	how	to	act,	
particularly	 in	case	of	a	 (potential)	 conflict	between	 the	 rights	and	 interest	of	 (future)	parents	and	
their	 (future)	 children.	 Thus,	 various	medical	 interventions	 conducted	on	embryos	and	 fetuses	 can	
have	implications	for	(future)	children	and	their	rights.	It	is	clear	that	due	to	the	sensitive	nature	of	
the	 issue,	 it	 is	 unlikely	 to	 reach	 consensus.	 Yet	 under	 the	 current	 situation,	 such	 medical	
interventions	remain	unregulated	and	specific	guidance	 for	States	 is	 lacking.	 It	 is	 recommended	to	
explore	if	the	drafting	of	additional	and	legally	binding	standards	in	this	regard	is	feasible	or	that	
further	 guidance	 should	 be	 provided	 through	 recommendations	 and/or	 guidelines	 to	 Council	 of	
Europe	Member	States.		












capacity	 to	 consent	 shall	 only	 be	 carried	 out	 for	 their	 ‘direct	 benefit’.193	 It	 further	 holds	 that	
children’s	genetic	testing	shall	be	deferred	until	they	can	consent,	unless	such	delay	would	negatively	
impact	 their	 health	 or	 well-being	 (i.e.,	 in	 case	 the	 information	 allows	 a	 preventive	 measure	 or	
treatment).194	 In	 addition,	 the	 Protocol	 concerning	 Genetic	 Testing	 requires	 to	 weight	 privacy	
consideration	 in	 relation	 to	 the	 collection,	 saving,	 processing	 and	 communication	 of	 data	 derived	




reflects	 the	 concern	 that	 children	may	 be	 screened	 for	 incurable	 diseases	 or	 life-threatening	
situations	 before	 they	 are	 psychologically	 and	 emotionally	 mature	 to	 understand	 the	
implications.197	 The	 provision	 reflects	 a	 protective	 approach	 and	 upholds	 the	 principle	 of	 the	














protection	 and	 recognising	 children’s	 evolving	 capacities	 and	 their	 right	 to	 autonomy	 and	
receive	 information	on	their	health,	guidance	regarding	age	of	consent	 is	required,	as	well	as	
on	 the	measures	 that	 can	 be	 taken	 in	 order	 to	 ensure	 that	 the	 age	 limits	 are	 respected	 in	
practice	 by	 those	 concerned	within	 and	 outside	 the	 clinical	 setting.198	 Such	 guidance	 should	












3. Participation:	 Genetic	 testing	 of	 children	 requires	 authorization	 from	parents	 (or	 authority	 as	
prescribed	by	 law),	while	 the	 views	of	 the	 child	 should	be	 taken	 into	 consideration.199	 Yet,	 as	
previously	discussed,	guidance	is	required,	also	for	clinicians,	on	how	States	can	implement	the	




right	 to	 know	 the	 information	 collected	 and	derived	 from	his	 or	 her	 genetic	 testing,	 and	 that	
such	information	shall	be	‘accessible	to	the	persons	concerned	in	a	comprehensible	form’.200	In	
addition,	 it	 prescribes	 that	 the	 persons	 tested	 shall	 be	 provided	 with	 prior	 appropriate	
information,	 covering	 the	 purpose	 and	 nature	 of	 the	 test,	 as	 well	 as	 the	 implications	 of	
results.201	This	again	raises	the	issue	of	child-friendly	 information.	Guidance	is	required	on	the	
measures	 that	 should	 be	 put	 in	 place	 to	 ensure	 children	 are	 independently	 provided	 with	
child-friendly	information.	
4.2.5	Gender	modification	techniques	
Gender	 modification	 techniques	 (including	 decisions	 relating	 to	 conducting	 or	 refraining	 from	
treatment	and	surgical	 intervention),	particularly	 relating	 to	 transgender	and	 intersex	children,	 can	
have	irreversible	and	life-long	consequences	for	the	child.202	This	raises	legal	constraints	between	the	
wishes	of	parents,	the	assessment	of	the	medical	necessity	by	medical	professionals	and	the	rights,	














guidance	 on	 the	 issues	 these	 children	 are	 confronted	 with	 and	 on	 gender	 modification	
techniques	in	relation	to	children.	Considering	intersex	children,	the	CHRB	holds	that	medical	
interventions	 for	 persons	 not	 able	 to	 consent	 may	 only	 be	 carried	 out	 for	 their	 ‘direct	
benefit’.204	Yet	 it	 is	highly	disputed	whether	gender	modification	techniques	can	be	regarded	




open	 for	medically	 unnecessary	 and	 irreversible	 gender	modification	procedures,	with	 grave	
consequences	for	children’s	rights	and	well-being,	while	others	might	argue	that	unnecessarily	
delaying	such	interventions	is	neither	in	the	best	interests	of	the	child.	Specifically	In	relation	
to	 transgender	 children,	 there	 is	 no	 specific	 guidance	 on	when,	 and	 under	what	 conditions,	
children	 can	 have	 access	 to	 hormonal	 treatment	 to	 suppress	 puberty	 and	 avoid	 developing	
permanent	 and	 unwanted	 characteristics	 of	 their	 biological	 sex,	 or	 even	 surgical	
interventions,205	and	it	is	unclear	if	and	to	what	extent	the	CHRB	can	be	applied	in	this	context.	
Therefore,	more	guidance	 is	highly	needed,	as	well	as	additional	 standard-setting	 in	which	
the	 position	 of	 both	 transgender	 and	 intersex	 children	 is	 explicitly	 recognised.	 It	 is	 also	
recommended	 to	explore	 if	 the	drafting	of	 additional	 and	 legally	binding	 standards	 in	 this	
regard	 is	 feasible	 or	 that	 further	 guidance	 should	 be	 provided	 through	 recommendations	
and/or	 guidelines	 to	 Council	 of	 Europe	 Member	 States.	 The	 position	 of	 intersex	 and	












3. Participation:	 gender	 modification	 techniques	 on	 intersex	 children	 are	 generally	 conducted	
before	the	child	is	able	to	provide	consent.	Authorization	is	provided	by	the	parents	who,	even	




205	 	 Price-Minter,	 S.	 (2012),	 ‘Supporting	 Transgender	 Children:	 New	 Legal,	 Social	 and	 Medical	 Approaches’,	 Journal	 of	
Homosexuality	59,	pp.	428-429;	See	also	WPATH	(2011),	supra	note	116,	p.	18-21.	
206	See	Article	7	CRC.	
207	 CRC	 Committee,	General	 Comment	No.	 8	 (2006).	 The	 right	 of	 the	 child	 to	 protection	 from	 corporal	 punishment	 and	





adequate	 weight	 by	 parents	 and	 medical	 professionals.	 States	 should	 therefore	 be	
encouraged	 to	 strictly	 regulate	 gender	 modification	 techniques	 applied	 on	 children	 (e.g.	
ethical	committees),	guided	by	the	rights	of	the	child	and	the	general	principles	of	the	CRC.	
Again,	 the	Council	of	Europe	could	 facilitate	 this	process	by	exploring	 the	 feasibility	of	 the	
drafting	of	additional	and	 legally	binding	 standards	 in	 this	 regard	and/or	providing	 further	
guidance	through	recommendations	and/or	guidelines	to	Council	of	Europe	Member	States.	
4.2.6	Transplantation	care	
The	 Protocol	 concerning	 Transplantation	 holds	 as	 a	 general	 rule	 that	 removal	 of	 organs	 or	 tissues	
from	a	living	person	may	be	carried	out	only	for	the	therapeutic	benefit	of	the	recipient,	and	in	the	






and	 it	 is	 unclear	what,	 if	 any,	 special	measures	 of	 protection	 and	 assistance	 are	 available	 for	
children	 who	 are	 able	 to	 consent	 and	 make	 decisions	 relating	 to	 transplantation	 care	 under	
national	 law.	Therefore,	 it	 is	 recommended	 to	undertake	 efforts	 to	 establish	 such	measures	
and	to	make	them	available	for	all	children	involved.	
	
2. Participation:	 As	 previously	 discussed,	 participation	 in	 the	 context	 of	 transplantation	 care	
should	 be	 understood	 broadly,	 to	 include	 the	 child’s	 ability	 to	 participate	 and	 be	 heard	 in	
decision	making,	 as	well	 as	 in	 relation	 to	 his	 or	 her	 (legal)	 possibility	 to	 consent	 or	 object	 to	







rights.	Child	 participation	 and	 related	 practices	with	 regards	 to	 transplantation	 care	 should	
also	be	explored	as	part	of	 the	 recommended	 legal	mapping	across	national	 contexts	 in	 the	
Council	of	Europe	Member	States.	
	
3. Autonomy:	 The	 Protocol	 concerning	 Transplantation	 allows	 persons	 to	 donate	 organs	 for	 the	
benefit	of	a	recipient	with	whom	the	donor	has	a	close	personal	relationship	as	defined	by	law,	












the	donation	of	certain	organs.	 	Further	mapping	 is	 required	regarding	the	age	of	consent	to	




donor	 and,	 where	 appropriate,	 the	 person	 providing	 authorization,	 shall	 be	 provided	 with	





what	means	and	at	what	point	they	would	 like	to	end	their	 life,	provided	that	they	are	 ‘capable	of	
freely	 reaching	 a	 decision’.214	 Despite	 the	 CRC’s	 recognition	 of	 children’s	 evolving	 capacities,	 it	 is	
unlikely	that	children	are	thought	to	be	capable	of	exercising	these	rights	given	the	lack	of	European,	
let	 alone	 international	 consensus	 on	 such	 issues	 as	 euthanasia	 and	 the	 definition	 of	 futile	
treatment.215	As	 a	 result,	 and	given	 the	 sensitive	nature	of	 this	 issue,	 the	ECtHR	 found	 that	 States	
should	have	a	wide	margin	of	appreciation.216	In	relation	to	children’s	rights	and	biomedicine,	several	
challenges	 can	 be	 identified,	 in	 addition	 to	 the	 inherent	 tension	 with	 the	 children’s	 evolving	
capacities.	
	
1. Scope:	 the	 CHRB	 includes	 that	 previously	 expressed	 wishes	 relating	 to	 medical	 intervention	
‘shall	be	taken	into	account’.217	Yet	it	is	unclear	if	and	to	what	extent	can	CHRB	refers	to	end	of	
life	decisions	and	whether	such	directives	can	or	should	be	respected	if	expressed	by	a	person	
who	never	 reached	 the	 age	of	 legal	 capacity.	 In	 any	 case,	 it	 remains	 unclear	 if	 the	 provisions	
related	 to	 children	 can	and	 should	be	applied	 in	 this	 context	and	 further	 guidance	 should	be	
provided.	
	
2. Right	 to	be	heard:	 the	 issue	of	 end	of	 life	 decisions	 raises	 the	 issue	of	 the	 child’s	 right	 to	 be	
heard	 and	 have	 his	 or	 her	 views	 considered	 in	 the	 decision-making	 process,	 including	 in	
















that	his	or	her	opinions	should	be	taken	 into	account	as	an	 increasingly	determining	 factor,	 in	
accordance	with	 his	 or	 her	maturity	 and	 evolving	 capacities.218	This	 requires	 guidance	 at	 the	
European	level,	on	how	States	should	implement	their	margin	of	appreciation	in	the	context	







In	 this	 report,	 we	 have	 assessed	 whether	 the	 existing	 body	 of	 international	 and	 European	 law	
provides	adequate	protection	to	the	human	rights	of	children	in	the	context	of	biomedicine.	The	aim	
of	 this	 report	 is	 to	 provide	 recommendations	 to	 the	 Council	 of	 Europe	 for	 an	 action	 plan	 at	 the	
intergovernmental	level.	We	believe	that	there	is	a	need	for	action,	roughly	in	four	different	ways:	1)	
Providing	 guidance	 to	 States	 targeted	 at	 domestic	 legislation	 and	 practices;	 2)	 Awareness	 raising,	
capacity	 building,	 education	 and	 training;	 3)	 Additional	 standard-setting,	 among	 others	 with	 a	
particular	 focus	 on	 child-friendly	 systems;	 and	 4)	 Further	 research,	 in	 particular	 the	 mapping	 of	
national	legislative	frameworks	and	practices	in	the	Council	of	Europe	Member	States.	Chapter	4	has	
provided	specific	recommendations	in	relation	to	the	biomedical	challenges	identified	in	the	Uppsala	
Report	 (see	 also	Annex	 I).	 In	 addition,	 some	general	 recommendations	 are	made	 in	 paragraph	5.2	
(see	also	Annex	II).		
In	 general,	 it	 can	 be	 concluded	 that	 the	 specific	 position	 of	 children	 has	 been	 acknowledged	 in	
international	 and	 European	 biomedical	 standards,	 even	 though	 these	 are	 primarily	 targeted	 at	
human	beings	in	general.	Children	are	often	addressed	as	a	different	category	of	human	beings,	that	
is	to	say,	as	part	of	the	group	of	vulnerable	persons	entitled	to,	or	the	object	of,	special	consideration	
and	protection.	To	 the	extent	 that	 there	are	child-specific	biomedical	 standards	 these	 tend	to	 lean	
towards	protection	of	the	rights	and	interests	of	children	–	particularly	those	who	cannot	consent	–	
rather	 than	 recognising	 children’s	 evolving	 capacities	 and	 growing	 autonomy	 as	 well	 as	 their	




and	 views,	 thus	 acknowledging	 their	 dignity	 as	 empowerment.	 This	 has	 implications	 for	 all	 the	
biomedical	areas	of	concerns	identified	in	the	Uppsala	Report	and	themes	addressed	in	this	report,	
and	 relate	 to	gaps	and	challenges	concerning	 the	 following	 issues:	1)	 consent,	autonomy	and	 legal	
representation	(by	parents	and	others);	2)	participation;	and	3)	access	to	justice	and	remedies.	These	




children	 as	 such	 and/or	 the	 consent	 of	 parents	 (or	 others),	 which	 ultimately	 relates	 to	 children’s	
evolving	autonomy.	The	particular	complexity	of	the	role	of	medical	professionals	in	this	regard	is	not	
carefully	considered	either.	In	addition,	we	found	that	international	and	European	standards	are	not	
sufficiently	 clear	 on	 the	 precise	 meaning	 of	 consent	 and	 objection,	 and	 their	 implications	 for	
children’s	autonomy.	This	has	implications	for	all	of	the	biomedical	themes	discussed	in	this	report,	
although	 it	 should	 be	 acknowledged	 that	 in	 relation	 to	 some	 themes	 international	 and	 European	
standards	do	not	recognise	the	specific	position	of	children	at	all.	This	is	true	for	gender	modification	
techniques,	research	on	embryos	and	foetuses,	preconceptional	and	prenatal	interventions	and	end	
of	 life	 decisions,	 and	 should	 be	 understood	 in	 light	 of	 the	 controversial	 nature	 and/or	 particular	




this	process	by	organising	expert	meetings,	 seminars	or	conferences	on	 these	matters.	 In	addition,	
we	 recommend	 to	 assess	 the	 feasibility	 of	 developing	 additional	 legally	 binding	 standards	 to	 close	








biomedical	 research,	 position	 of	 parents	 and	 other	 legal	 representatives,	 role	 of	 medical	
professionals	 etc.)	 and	 practice.	 It	 is	 recommended	 that	 the	 Council	 of	 Europe	 provides	 more	
guidance	on	the	balancing	of	autonomy	and	legal	representation	in	specific	biomedical	arenas.	This	
can	be	done	by	the	development	of	guidelines	similar	to	the	Guidelines	on	child-friendly	health	care	
and	child-friendly	 justice.	However,	one	could	also	think	of	practical	 tools,	 including	the	drafting	of	
models	for	laws/legislation,	national	strategies	or	professional	guidelines.	It	also	seems	important	to	
conduct	or	commission	a	mapping	of	the	legislation	within	the	47	Council	of	Europe	Member	States	
to	 identify	and	better	understand	 the	 realities	on	 the	ground.	The	mapping	 should	 cover	 the	 legal	
and	practical	aspects	relating	to	all	the	biomedical	areas	explored	in	this	report,	particularly	focusing	
on	 issues	 related	 to	 age	 limits,	 consent	 and	 objection,	 parental	 authority,	 child	 participation	 and	
related	 professional	 practices.	 Apart	 from	 this,	 the	 balancing	 of	 children’s	 evolving	 capacities	 and	
related	autonomy	and	children’s	 representation	 requires	knowledge	and	 skills.	 Therefore,	 it	 is	 also	
recommended	that	the	Council	of	Europe	considers	developing	practical	tools	that	can	contribute	to	




The	 second	 issue	 that	 emerged	 in	 this	 study	 relates	 to	 the	 child’s	 right	 to	 be	 heard	 and,	 broader,	
participation	rights.	The	right	to	be	heard	and	participate	 in	decision-making	must	be	ensured,	and	
the	child’s	views	must	be	taken	into	account	and	given	due	weight	in	accordance	with	the	child's	age	
and	maturity,	 and	 regardless	of	his	or	her	 legal	 ability	 to	 consent.	Whether	one	 is	 concerned	with	
biomedical	research,	health	care	or	end	of	life	decisions,	the	views	of	all	children	must	be	taken	into	
account,	 and	 age	 should	 not	 be	 a	 limiting	 factor	 in	 this	 regard.	 This	 is	 one	 of	 the	 most	 notable	
improvements	of	international	children’s	rights	instruments	and	has	received	prominent	attention	in	
European	 law	 and	 standards	 relating	 to	 children’s	 issues.	 On	 the	 basis	 of	 our	 analysis,	 it	 can	 be	
argued	that	biomedical	standards	do	not	always	(fully)	recognise	or	regulate	children’s	involvement	
in	decision	making	affecting	them.	It	is	therefore	strongly	recommended	that	the	Council	of	Europe	
expands	 its	 important	 (and	 leading)	 role	 in	 advocating	 for	 child-friendly	 health	 care	 and	 justice	
systems	 to	 all	 biomedical	 matters.	 Much	 guidance	 for	 States	 can	 be	 found	 in	 international	 and	
European	 standards	 (see	 e.g.	 the	 Council	 of	 Europe’s	 child-friendly	 justice	 and	 health	 care	
instruments,	which	are	grounded	in,	among	others,	the	CRC	and	the	case	law	of	the	European	Court	
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of	Human	Rights),	 but	 these	 require	 adaptation	 to	 the	 specific	 context	of	 the	different	biomedical	
issues.	Participation	assumes	that	each	child	is	entitled	to	child-friendly	information,	assistance	and	
empowerment	in	light	of	his	or	her	age	and	maturity.	In	this	regard,	it	is	recommended	to	also	invest	
in	 practical	 skills	 of	 medical	 professionals	 and	 other	 stakeholders,	 e.g.	 on	 communication	 with	
children	(and	their	parents).		
3)	Access	to	justice	
A	 third	 cross-cutting	 theme	 is	 access	 to	 justice,	 which	 is	 an	 essential	 element	 of	 human	 rights	
protection	 of	 individuals,	 including	 children,	 and	 the	 possibility	 to	 enforce	 human	 rights.	
International	 and	 European	 biomedical	 standards	 are	 limited	 in	 the	way	 they	 recognise	 children’s	
rights	to	access	to	justice	and	to	an	effective	remedy,	while	these	rights	matter	and	ought	to	be	given	
careful	consideration.	Given	its	general	acceptance,	the	principle	of	access	to	justice	does	not	require	













concerned	 and/or	 others.	 It	 is	 therefore	 argued	 that,	 particularly	with	 respect	 to	 children,	 it	were	
better,	with	respect	to	all	the	interventions	falling	within	the	realm	of	the	seven	areas	of	concern,	to	
only	make	distinctions	that	are	commensurate	with	risks	and	burdens	of	the	persons	concerned.	
A	 second	observation	 relates	 to	 the	 role	of	medical	professionals,	with	 respect	 to	both	biomedical	
research	 and	 care.	We	would	 like	 to	 underscore	 that	 the	 particular	 complexity	 of	 the	 role	 of	 the	
medical	professionals	in	connection	with	the	child-parent	relationship	and	the	role	and	responsibility	
of	 the	 State	 for	 children’s	 and	 parents’	 rights	 requires	 ongoing	 attention	 and	 calls	 for	 supportive	
tools,	 such	 as	 an	 exchange	 of	 professional	 standards	within	 the	 Council	 of	 Europe.	 This	 should	 be	
organised	 around	 specific	 biomedical	 themes	 and	 recognise	 the	 essential	 safeguarding	 role	 of	
medical	 professionals	 in	 relation	 to	 the	 protection	 of	 fundamental	 rights	 of	 individuals	 against	
unlawful	 interference	 by	 States.	 With	 regard	 to	 children,	 medical	 professionals	 also	 have	 a	
safeguarding	role	to	play	in	light	of	the	child-parent	relationship	and	this	requires	specific	education	











and	 concern	 issues	 such	 as	 data	 collection,	 access	 to	 medical	 files	 and	 the	 storage	 of	 biological	
material.	 It	 would	 be	 recommended	 to	 include	 all	 of	 these	 issues	 in	 the	 legal	mapping	 suggested	
above.		
Finally,	 we	 would	 like	 to	 reiterate	 the	 importance	 of	 recognising	 the	 role	 of	 non-state	 actors,	
including	 businesses,	 such	 as	 pharmaceutical	 companies	 and	 insurance	 companies,	 and	 research	
institutes.	 It	 is	 recommended	 that	 the	 Council	 of	 Europe	 further	 explores	 the	 meaning	 of	 the	
children’s	rights	and	business	principles,	based	on	the	UN	Guiding	Principles	on	Business	and	Human	








Uppsala	 Report,	 and	 identify	 groups	 of	 children	 that	 so	 far	 have	 not	 or	 hardly	 been	 the	 object	 of	
standard	 setting	 and	 assess	 the	 feasibility	 of	 additional	 standard-setting,	 either	 through	 legally	





to	 be	 heard,	 participation	 rights	 and	 the	 right	 to	 access	 to	 justice	 should	 be	 given	 careful	
consideration	as	well.	
2.	 Conduct	 or	 commission	 a	 mapping	 of	 the	 legislation	 within	 the	 47	 Council	 of	 Europe	Member	
States	 related	 to	 biomedical	 issues,	 including	 legislation	 on	 health	 care	 and	 research,	 age	 limits,	










3.	 Promote	 the	 development	 of	 skills	 and	 knowledge	 with	 respect	 to	 the	 balancing	 of	 children’s	
evolving	 capacities	 and	 related	 autonomy	 and	 children’s	 representation.	 This	 may	 imply	 the	




systems	 in	 all	 other	 areas	 of	 biomedicine,	 building	 on	 the	 existing	 standards	 and	 experience	 and	
emphasising	 children’s	 right	 to	 participate	 effectively	 in	 decision-making	 affecting	 them,	 and	 their	
right	to	access	justice	and	seek	effective	remedies.	
5.	 Invest	 in	 awareness-raising,	 information/education	 and	 training	 for	 domestic	 legislators,	 policy	
makers,	medical	professionals	and	children	and	their	 families	on	access	 to	 justice	 in	 the	context	of	
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assistance	are	available	for	children	who	are	 legally	able	to	consent	to	biomedical	research.	 It	 is	
recommended	 that	 such	 children	 receive	 special	 assistance	 and	 safeguards	 in	 exercising	 their	
right	to	consent	and	make	decisions	in	the	context	of	biomedical	research.	Therefore,	the	Council	
of	 Europe	 is	 recommended	 to	undertake	efforts	 to	 establish	 such	measures	 and	 to	make	 them	
available	for	all	children	participating	in	biomedical	research.	
2. The	 Council	 of	 Europe	 is	 recommended	 to	 publish	 clarifications	 in	 relation	 to	 the	 distinction	
between	 the	 right	 of	 the	 child	 to	 consent,	 object,	 and	 effectively	 participate	 in	 biomedical	
research.	In	that	regard,	participation	should	be	understood	broadly	as	the	obligation	of	decision-
makers	 (e.g.,	 parents,	 medical	 professionals)	 to	 hear	 and	 consider	 the	 views	 of	 the	 child	
throughout	 the	 research	 process,	 irrespective	 of	 the	 child’s	 legal	 capacity	 to	 independently	
consent	 or	 object.	 In	 addition,	 the	 child’s	 right	 to	 participate	 requires	 research	 bodies	 and/or	
medical	 professionals	 to	 ensure	 that	 research	 procedures	 are	 designed	 in	 a	 child-sensitive	
manner,	 and	 that	 mechanisms	 are	 in	 place	 to	 encourage	 child	 participation.	 Special	 attention	
should	be	paid	 to	 the	elements	of	 ‘consent’	and	 ‘objection’	of	 the	child	 to	biomedical	 research.	
The	Council	of	Europe	is	therefore	recommended	to	provide	further	guidance,	as	well	as	practical	
measures,	 to	 enable	 children	 to	 exercise	 their	 right	 to	participate	 and	be	heard,	 and	 to	 ensure	
that	medical	professionals	reach	ethical	and	professional	decisions	in	cases	of	children’s	objection	
to	biomedical	research.	
3. The	 Council	 of	 Europe	 is	 recommended	 to	 emphasise	 the	 obligation	 of	 States	 to	 deliver	 child-
friendly	information	for	child	research	participants	and	their	parents.	To	that	end,	the	Council	of	




in	 the	context	decision-making	by	parents,	or	 legal	 representatives,	or	medical	professionals,	 in	
relation	to	child	participation	 in	research.	This	can	be	achieved	by	guiding	States	with	regard	to	
the	 discretion	 of	medical	 professionals	 and	 parents	 in	 decision-making,	 and	 on	 how	 States	 can	





Such	 guidance	 should	 focus	 on	 the	 accommodation	 of	 the	 child’s	 evolving	 age	 and	maturity	 in	
biomedical	research,	and	assist	 in	determining	what	mechanisms	should	be	established	that,	on	
the	 one	 hand,	 recognise	 the	 child’s	 evolving	 capacities,	 and	 on	 the	 other,	 avoid	 the	 negative	
implications	 of	 withdrawing	 from	 research.	 The	 guidance	 should	 also	 focus	 on	 ensuring	 that	
persons	and	organisations	responsible	for	a	research	project	enjoy	stability	in	their	research	and	
procedures.	
6. The	 Council	 of	 Europe	 is	 recommended	 to	 assist	 States	 in	 establishing	 legal	 protection,	 setting	
redress	 and	 complaints	 procedure	 and	 providing	 appropriate	 remedies	 for	 children	 and	 their	
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assistance	are	available	 for	children	who	are	 legally	able	 to	consent	 to	care	and	treatment.	 It	 is	
recommended	 that	 such	 children	 receive	 special	 assistance	 and	 safeguards	 in	 exercising	 their	
rights,	 for	 example	 in	 relation	 to	 receiving	 information,	 access	 to	 justice	 or	 other	 support.	
Therefore,	the	Council	of	Europe	is	recommended	to	stimulate	and	support	States	in	establishing	
such	measures	and	to	make	them	available	for	all	children	undergoing	health	care.	
9. The	 Council	 of	 Europe	 is	 recommended	 to	 assist	 States	 to	 fully	 implement	 the	 right	 to	 an	
equitable	health	care	for	all	children	by	publishing	detailed	and	concrete	guidance.	In	that	regard,	
it	 should	 be	 noted	 that	 the	 right	 to	 an	 equitable	 health	 care	 does	 not	 only	 require	 equal	
availability,	but	also	concern	accessibility,	acceptability	and	quality	health	care.	
10. The	Council	 of	 Europe	 is	 recommended	 clarify	 the	distinction	between	 the	 right	of	 the	 child	 to	
consent,	 object,	 and	 effectively	 participate	 in	 biomedical	 care	 and	 treatment.	 In	 that	 regard,	




Europe	 is	 recommended	 to	 conduct	 a	 mapping	 of	 the	 legal	 status	 (and	 related	 practices)	 of	
children	 in	 relation	 to	 consent,	 objections	 and	 participation	 in	 health	 care	 across	 national	
contexts,	 and	 it	 is	 recommended	 that	 such	 mapping	 forms	 part	 of	 the	 Council	 of	 Europe’s	
roadmap.	
11. The	Council	of	Europe	 is	 recommended	to	 identify,	by	way	of	a	study,	 the	elements	relevant	 to	
biomedical	 treatment	 that	 require	 child-friendly	 adaptation	 in	 health-related	 policies,	 services,	
practices	and	monitoring	mechanisms.	
12. The	 Council	 of	 Europe	 is	 recommended	 to	 guide	 States	 on	 how	 to	 find	 appropriate	 balance	
between	the	best	interests	and	health	of	children,	the	concerns	and	wishes	of	parents,	and	public	
health	 and	 medical	 standards.	 Such	 guidance	 should	 be	 child-focused,	 emphasising	 the	 best	
interests	 of	 the	 child	 and	 the	 child’s	 evolving	 capacities	 as	 primary	 considerations	 in	 decision-
making	and	policy	design.		














15. The	 Council	 of	 Europe	 is	 recommended	 to	 establish	 guidelines	 for	 States	 and	 identify	 best	




take	 a	 balanced	 approach	 between	 protecting	 children	 and	 recognising	 children’s	 evolving	
capacities	and	 their	 right	 to	autonomy	and	 to	 receive	 information	on	 their	health	 in	 relation	 to	
genetic	 testing.	Such	guidance	should	address	 the	age	of	 consent	 for	genetic	 testing,	as	well	 as	
the	measures	that	can	be	taken	to	ensure	that	the	age	 limits	are	respected	 in	practice	by	those	
concerned	 within	 and	 outside	 the	 clinical	 setting.	 The	 guidance	 should	 also	 allow	 for	 a	 child-
specific	 evaluation,	 taking	 into	 account	 the	 particular	 child’s	 needs,	 maturity	 and	 the	 type	 of	
genetic	test.	
17. The	 Council	 of	 Europe	 is	 recommended	 clarify	 what,	 if	 any,	 special	 protection	 and	 assistance	
should	 be	 available	 for	 children	 who	 are	 legally	 able	 to	 consent	 to	 genetic	 testing.	 It	 is	
recommended	that	such	children	are	 recognised	as	vulnerable,	and	be	provided	with	additional	
support	 and	 safeguards.	 Therefore,	 it	 is	 recommended	 that	 the	 Council	 of	 Europe	 undertakes	
efforts	to	establish	such	measures	and	make	them	available	for	all	children	involved	or	affected.	
18. The	Council	of	 Europe	 is	 recommended	 to	publish	guidance	 for	 States	and	clinicians	on	how	 to	
implement	 the	 child’s	 right	 to	 have	 his	 or	 her	 opinion	 taken	 into	 consideration	 in	 relation	 to	




in	 place	 to	 ensure	 children	 are	 provided	 with	 child-friendly	 information	 in	 relation	 to	 genetic	
testing.	
Gender	modification	techniques	
20. The	 Council	 of	 Europe	 is	 recommended	 to	 provide	 guidance,	 as	 well	 as	 additional	 standard-
setting,	 for	 States	 in	 relation	 to	 gender	 modification	 techniques	 concerning	 intersex	 and	
transgender	 children.	 In	 relation	 to	 intersex	 children,	 guidance	 and	 standards	 should	 tackle,	 on	
the	 one	 hand,	 the	medically	 unnecessary	 and	 irreversible	 gender	modification	 procedures	 and	
their	 potential	 grave	 consequences	 for	 children’s	 rights	 and	 well-being,	 and	 on	 the	 other,	 to	
recognise	 that	 delaying	 certain	 interventions	 can	 also	 negatively	 impact	 the	 best	 interests	 of	
children.	For	transgender	children,	guidance	and	standards	are	required	to	determine	when,	and	
under	 what	 conditions,	 children	 can	 have	 access	 to	 hormonal	 treatment	 and	 surgical	
interventions,	and	what	role	does	the	CHRB	play	 in	that	regard.	 It	 is	recommended	to	explore	if	
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the	drafting	of	 additional	 and	 legally	 binding	 standards	 in	 this	 regard	 is	 feasible	or	 that	 further	
guidance	 should	be	provided	 through	 recommendations	and/or	guidelines	 to	Council	of	Europe	
Member	States.	The	position	of	intersex	and	transgender	children	should	also	be	explored	as	part	
of	 the	abovementioned	 recommended	 legal	mapping	across	national	 contexts	 in	 the	Council	 of	
Europe	Member	States.	
21. The	Council	of	Europe	 is	 recommended	to	explore	 the	practices	 relating	 to	gender	modification	
techniques	 on	 intersex	 or	 transgender	 children	 (e.g.	 sterilization,	 irreversible,	 involuntary	 and	
medically	unnecessary	procedures,	etc.)	and	determine	their	implications	in	relation	to	the	child’s	
right	 to	 protection	 and	 to	 identity.	 In	 that	 regard,	 the	 Council	 of	 Europe	 is	 recommended	 to	
provide	 further	 guidance	 to	 States	 on	how	 to	 implement	 and	ensure	 the	 rights	 of	 intersex	 and	
transgender	children	to	protection	and	identity	in	the	context	of	gender	modification	techniques.		
22. The	 Council	 of	 Europe	 is	 recommended	 to	 encourage	 States	 to	 strictly	 regulate	 gender	
modification	 techniques	 applied	 on	 children,	 and	 ensure	 that	 such	 regulative	 bodies	 and/or	
standards	 are	 guided	 by	 the	 rights	 of	 the	 child	 and	 the	 general	 principles	 of	 the	 CRC,	 and	 in	
particular	the	right	of	the	child	to	be	heard	and	participate	in	decision-making.	Again,	the	Council	
of	 Europe	 could	 facilitate	 this	 process	 by	 exploring	 the	 feasibility	 of	 drafting	 of	 additional	 and	






make	 decisions	 in	 the	 context	 of	 transplantation	 care,	 and	 it	 is,	 therefore,	 recommended	 to	
undertake	efforts	to	establish	such	measures	and	to	make	them	available	for	all	children	involved.	
24. The	Council	of	Europe	 is	 recommended	to	provide	clarification	 in	relation	to	the	distinction	and	
relations	between	the	child’s	right	to	consent,	object	and	effectively	participate	in	the	context	of	
transplantation	care.	 In	particular,	guidance	 is	 required	 in	 relation	 to	 the	evaluation	of	a	 child’s	
objection,	and	the	measures	 that	can	be	taken	by	medical	professionals	 to	 reach	a	professional	
and	ethical	decision,	while	taking	into	account	children’s	participation	rights	and	conditions	under	
which	 children	 should	be	enabled	 to	exercise	 these	 rights.	 Furthermore,	 child	participation	and	
related	 practices	 with	 regards	 to	 transplantation	 care	 should	 also	 be	 explored	 as	 part	 of	 the	
recommended	legal	mapping	across	national	contexts	in	the	Council	of	Europe	Member	States.	
25. The	Council	of	Europe	is	recommended	to	address	the	issue	of	autonomy	in	relation	to	children	in	
the	 context	 of	 transplantation	 care.	 In	 particular,	 the	 extent	 of	 children’s	 ability	 to	 exercise	
autonomy	 and	make	 free	 and	 informed	decisions	 on	 health	matters,	 especially	with	 regards	 to	
irreversible	 decisions	 such	 as	 donation	 of	 certain	 organs,	 should	 be	 addressed.	 Therefore,	 the	
Council	 of	 Europe	 is	 recommended	 to	 conduct	 legal	 mapping	 regarding	 the	 age	 of	 consent	 to	
transplantation	care	and	related	practices	across	national	contexts,	and	how	the	principle	of	the	
child’s	evolving	capacities	is	implemented	in	that	regard.	
26. The	 Council	 of	 Europe	 is	 recommended	 to	 provide	 guidance	 for	 States	 on	 how	 to	 ensure	 that	





27. The	Council	of	Europe	 is	 recommended	to	provide	further	guidance	for	States	 in	relation	to	the	
applicability	of	the	CHRB	to	the	issue	of	end	of	life	decisions	of	children.	
28. The	Council	of	Europe	 is	 recommended	 to	develop	guidance	 in	 relation	 to	end	of	 life	decisions,	














Uppsala	 Report,	 and	 identify	 groups	 of	 children	 that	 so	 far	 have	 not	 or	 hardly	 been	 the	 object	 of	
standard	 setting	 and	 assess	 the	 feasibility	 of	 additional	 standard-setting,	 either	 through	 legally	





to	 be	 heard,	 participation	 rights	 and	 the	 right	 to	 access	 to	 justice	 should	 be	 given	 careful	
consideration	as	well.	
2.	 Conduct	 or	 commission	 a	 mapping	 of	 the	 legislation	 within	 the	 47	 Council	 of	 Europe	Member	
States	 related	 to	 biomedical	 issues,	 including	 legislation	 on	 health	 care	 and	 research,	 age	 limits,	





3.	 Promote	 the	 development	 of	 skills	 and	 knowledge	 with	 respect	 to	 the	 balancing	 of	 children’s	
evolving	 capacities	 and	 related	 autonomy	 and	 children’s	 representation.	 This	 may	 imply	 the	




systems	 in	 all	 other	 areas	 of	 biomedicine,	 building	 on	 the	 existing	 standards	 and	 experience	 and	
emphasising	 children’s	 right	 to	 participate	 effectively	 in	 decision-making	 affecting	 them,	 and	 their	
right	to	access	justice	and	seek	effective	remedies.	
5.	 Invest	 in	 awareness-raising,	 information/education	 and	 training	 for	 domestic	 legislators,	 policy	
makers,	medical	professionals	and	children	and	their	 families	on	access	 to	 justice	 in	 the	context	of	
biomedicine.	 This	may	 imply	 facilitating	 the	 exchange	 of	 good	 practices	 among	 Council	 of	 Europe	
Member	States.	
	
	
	
